In particular, Uçar et al. [30] demonstrated that the number of KRAS mutations in metastatic colorectal cancer (mCRC) is significantly associated with worse clinical outcomes, supporting the role of KRAS as a negative prognostic biomarker. The gene discussed is KRAS; the disease is metastatic colorectal cancer.